DBV Technologies Shares Consolidate Late Afternoon Following a 14% Drop Over Seven Days
DBV Technologies shares saw a slight increase of 0.14% this Tuesday, March 17, 2026, trading at €3.465, after experiencing significant selling pressure over the past week. Over the last seven days, the stock has declined by 14.23%, triggering a signal of abnormal fluctuation. This movement contrasts with the performance of the CAC 40, which is up by 0.88% during the session.
DBV Technologies has undergone a noticeable weekly correction, bringing its price close to the technical support level at €3.43. The monthly volatility of the stock stands at 17.31%, reflecting significant price ranges during the recent period. This movement occurs in a moderately tense global environment, with the VIX remaining at 27.19, a level indicating persistent nervousness in international markets. The stock is trading significantly below its 50-day moving average of €3.64, confirming an unfavorable short-term dynamic. The RSI is at 38, signaling a gradual approach to the oversold zone without yet crossing it.
Long-Term Outlook and Technical Indicators
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Over a longer horizon, DBV Technologies has shown a spectacular recovery of 293.8% over the past twelve months. The performance over three months remains slightly positive at 1.02%, placing the recent correction in a consolidation phase after a significant bullish phase. The stock is also trading well above its 200-day moving average, set at €2.49, maintaining a bullish backdrop over the long term. The technical resistance identified at €4.27 remains distant from the current prices, while a beta of 0.43 illustrates a moderate correlation of the stock with overall market movements. The MACD signal, slightly negative, further confirms the persistence of short-term pressure on the stock.
Perte nette trimestrielle de (33,2) millions de dollars ; trésorerie de 69,8 millions de dollars au 30/09/2025 suite à un financement partiel (125,5 M$ reçu) et un programme ATM ; dépenses opérationnelles élevées principalement en R&D (83,8 M$ sur 9 mois). Trésorerie estimée suffisante jusqu'au T3 2026 mais incertitude significative persiste.
Risks mentioned
Incertitude significative sur la continuité d'exploitation (trésorerie insuffisante pour couvrir 12 prochains mois)
Dépendance aux financements externes (PIPE, ATM et autres levées de fonds)
Accès futur aux capitaux soumis aux conditions du marché et à l'intérêt des investisseurs
Dépendance aux résultats de l'étude de phase 3 VITESSE pour accélération d'exercices de BSA et financements supplémentaires
Opportunities identified
Financement pouvant atteindre 306,9 millions de dollars via PIPE
Programme ATM pouvant générer jusqu'à 150,0 millions de dollars
Potentiel réglementaire et commercial du patch Viaskin® Peanut (BLA et lancement aux États-Unis si approuvé)
Possibilité d'exercices supplémentaires de bons de souscription si certains critères sont atteints
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
